Table 1.

Protease-activated receptor (PAR) expression in human cancers. Gene Expression Profiling Interactive Analysis (GEPIA, http://gepia.cancer-pku.cn/), a newly developed online platform using RNA sequencing expression data from the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression projects (GTEx) was used to compare tumor versus normal samples in numerous cancer types. The table summarizes the types of cancers that exhibit either upregulation or downregulation of PARs, compared to normal tissue. ND (not detected).

PARs	Cancers with Upregulated PARs	Cancers with Downregulated PARs
PAR1	Breast invasive carcinoma Colon adenocarcinoma Lymphoid neoplasm diffuse large B-cell lymphoma Esophageal carcinoma Glioblastoma multiforme Head and neck squamous cell carcinoma Kidney renal clear cell carcinoma Brain lower grade glioma Ovarian serous cystadenocarcinoma Pancreatic adenocarcinoma Rectum adenocarcinoma Stomach adenocarcinoma Thymoma	Kidney chromophobe Kidney renal papillary cell carcinoma β
PAR2	Cervical squamous cell carcinoma and endocervical adenocarcinomaColon adenocarcinoma Esophageal carcinoma Glioblastoma multiforme Acute myeloid leukemia Lung adenocarcinoma Lung squamous cell carcinoma Ovarian serous cystadenocarcinoma Pancreatic adenocarcinoma Prostate adenocarcinoma Rectum adenocarcinoma Stomach adenocarcinoma Testicular germ cell tumors Uterine corpus endometrial carcinoma Uterine carcinosarcoma	Kidney chromophobe Skin cutaneous melanoma
PAR3	Breast invasive carcinoma Esophageal carcinoma Head and neck squamous cell carcinoma Pancreatic adenocarcinoma Stomach adenocarcinoma	ND
PAR4	Kidney renal clear cell carcinoma Pancreatic adenocarcinoma	Acute myeloid leukemia Lung adenocarcinoma Lung squamous cell carcinoma Testicular germ cell tumors Thyroid carcinoma